v3.26.1
SCHEDULE OF BUSINESS SEGMENT (Details)
 12 Months Ended
Dec. 31, 2025
USD ($)
Dec. 31, 2025
SGD ($)
Dec. 31, 2024
SGD ($)
Dec. 31, 2023
SGD ($)
IfrsStatementLineItems [Line Items]        
Revenue $ 252,265 $ 324,387 $ 69,501
Private blood banking expenses (52,875) (67,992) (17,121)
Operating results (3,005,137) (3,864,306) (2,358,216) (4,223,088)
Non-current assets 3,361,053 4,321,978 4,067,046  
Total assets 6,209,622 7,984,953 10,067,749  
Non-current liabilities 328,266 422,117 417,338  
Total liabilities 879,762 1,131,286 1,023,960  
Balance $ 5,329,860 6,853,667 9,043,789 $ 11,244,155
Immune cell therapy [member]        
IfrsStatementLineItems [Line Items]        
Revenue    
Private blood banking expenses    
Operating results   (3,705,474) (2,288,907)  
Non-current assets   3,095,610 3,255,888  
Total assets   5,930,746 9,059,086  
Non-current liabilities   369,535 394,311  
Total liabilities   457,066 871,435  
Balance   7,125,613 8,246,154  
CBU service & related therapy [member]        
IfrsStatementLineItems [Line Items]        
Revenue   324,387 69,501  
Private blood banking expenses   (67,992) (17,121)  
Operating results   (158,832) (69,309)  
Non-current assets   1,226,368 811,158  
Total assets   2,054,207 1,008,663  
Non-current liabilities   52,582 23,027  
Total liabilities   674,220 152,525  
Balance   (271,946) 797,635  
Reportable segments [member]        
IfrsStatementLineItems [Line Items]        
Revenue   324,387 69,501  
Private blood banking expenses   (67,992) (17,121)  
Operating results   (3,864,306) (2,358,216)  
Non-current assets   4,321,978 4,067,046  
Total assets   7,984,953 10,067,749  
Non-current liabilities   422,117 417,338  
Total liabilities   1,131,286 1,023,960  
Balance   $ 6,853,667 $ 9,043,789